Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a strategic partnership with the National Medical Center for Infectious Disease/Beijing Ditan Hospital Capital Medical University. The collaboration will focus on the development of HIV drugs, encompassing various aspects of research and development.
Collaborative Efforts in HIV Drug Development
The partnership aims to advance clinical trials of innovative AIDS drugs and conduct post-marketing clinical research of existing medications. Additionally, the two entities will work together on the preparation of a joint laboratory to train talent, as well as the joint filing of scientific research projects. While the financial details of the agreement have not been disclosed, the scope of the collaboration indicates a significant commitment to enhancing HIV treatment and research in China.
Establishment of the China AIDS Prevention and Control Innovative Drug Research Demonstration Base
A key outcome of this strategic partnership is the establishment of the China AIDS Prevention and Control Innovative Drug Research Demonstration Base. This base will serve as a hub for innovative research and development in the field of HIV/AIDS, aiming to improve prevention strategies and drug therapies.-Fineline Info & Tech
